Spine Bone Texture Assessed by Trabecular Bone Score in Active and Controlled Acromegaly : A Prospective Study
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Acromegalic patients have an increased vertebral fracture (VFx) risk due to bone quality reduction, independently of bone mineral density (BMD).
OBJECTIVE: The aim of the study is to describe bone quality in acromegaly, measured by trabecular bone score (TBS), a noninvasive index for assessing bone microarchitecture.
METHODS: We collected data from 18 patients (13 female, age 56.2 ± 15 years) newly diagnosed with acromegaly. Thirty-six age- and sex-matched healthy controls were also recruited. Pituitary function, bone and calcium-phosphorous metabolism, and BMD at spine and femur and TBS (by dual-energy x-ray absorptiometry) were assessed in acromegalic patients at diagnosis and 12 months after the achievement of insulin-like growth factor 1 (IGF-1) normalization.
RESULTS: At diagnosis, BMD and the VFx prevalence were comparable between patients and controls (28.3 ± 5.9 vs 27.6 ± 3.7 and 11% vs 8.3%), whereas TBS was significantly lower in acromegalic patients (1.20 ± 0.13 vs 1.30 ± 0.06; P < .001) and carboxyterminal telopeptide (CTX) and osteocalcin were significantly higher compared to controls (707 ± 365.7 vs 371 ± 104.1 pg/mL; P = .001 and 31.6 ± 15.4 vs 17.0 ± 5.7 ng/mL; P = .001, respectively). One year after IGF-1 normalization, a significant reduction of bone turnover indexes was observed in the group of acromegalic patients surgically cured (osteocalcin decrease of 61.2%, CTX decrease of 60.3%) compared to the ones controlled by medical therapy (osteocalcin decrease of 39%, CTX decrease of 40.7%; P = .01 and P = .001, respectively). Despite these findings, no TBS or BMD variations were observed.
CONCLUSION: Acromegalic patients have impaired bone quality despite normal density. Achieving normal growth hormone secretion rapidly leads to the normalization of bone turnover.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Journal of the Endocrine Society - 5(2021), 8 vom: 01. Aug., Seite bvab090 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sala, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 24.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1210/jendso/bvab090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32742298X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32742298X | ||
| 003 | DE-627 | ||
| 005 | 20231225200742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jendso/bvab090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM32742298X | ||
| 035 | |a (NLM)34195527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sala, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spine Bone Texture Assessed by Trabecular Bone Score in Active and Controlled Acromegaly |b A Prospective Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Acromegalic patients have an increased vertebral fracture (VFx) risk due to bone quality reduction, independently of bone mineral density (BMD) | ||
| 520 | |a OBJECTIVE: The aim of the study is to describe bone quality in acromegaly, measured by trabecular bone score (TBS), a noninvasive index for assessing bone microarchitecture | ||
| 520 | |a METHODS: We collected data from 18 patients (13 female, age 56.2 ± 15 years) newly diagnosed with acromegaly. Thirty-six age- and sex-matched healthy controls were also recruited. Pituitary function, bone and calcium-phosphorous metabolism, and BMD at spine and femur and TBS (by dual-energy x-ray absorptiometry) were assessed in acromegalic patients at diagnosis and 12 months after the achievement of insulin-like growth factor 1 (IGF-1) normalization | ||
| 520 | |a RESULTS: At diagnosis, BMD and the VFx prevalence were comparable between patients and controls (28.3 ± 5.9 vs 27.6 ± 3.7 and 11% vs 8.3%), whereas TBS was significantly lower in acromegalic patients (1.20 ± 0.13 vs 1.30 ± 0.06; P < .001) and carboxyterminal telopeptide (CTX) and osteocalcin were significantly higher compared to controls (707 ± 365.7 vs 371 ± 104.1 pg/mL; P = .001 and 31.6 ± 15.4 vs 17.0 ± 5.7 ng/mL; P = .001, respectively). One year after IGF-1 normalization, a significant reduction of bone turnover indexes was observed in the group of acromegalic patients surgically cured (osteocalcin decrease of 61.2%, CTX decrease of 60.3%) compared to the ones controlled by medical therapy (osteocalcin decrease of 39%, CTX decrease of 40.7%; P = .01 and P = .001, respectively). Despite these findings, no TBS or BMD variations were observed | ||
| 520 | |a CONCLUSION: Acromegalic patients have impaired bone quality despite normal density. Achieving normal growth hormone secretion rapidly leads to the normalization of bone turnover | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a TBS | |
| 650 | 4 | |a acromegaly | |
| 650 | 4 | |a bone metabolism | |
| 650 | 4 | |a osteoporosis | |
| 700 | 1 | |a Malchiodi, E |e verfasserin |4 aut | |
| 700 | 1 | |a Carosi, G |e verfasserin |4 aut | |
| 700 | 1 | |a Verrua, E |e verfasserin |4 aut | |
| 700 | 1 | |a Cairoli, E |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrante, E |e verfasserin |4 aut | |
| 700 | 1 | |a Filopanti, M |e verfasserin |4 aut | |
| 700 | 1 | |a Eller-Vainicher, C |e verfasserin |4 aut | |
| 700 | 1 | |a Ulivieri, F M |e verfasserin |4 aut | |
| 700 | 1 | |a Spada, A |e verfasserin |4 aut | |
| 700 | 1 | |a Arosio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Chiodini, I |e verfasserin |4 aut | |
| 700 | 1 | |a Mantovani, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Endocrine Society |d 2017 |g 5(2021), 8 vom: 01. Aug., Seite bvab090 |w (DE-627)NLM272607959 |x 2472-1972 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2021 |g number:8 |g day:01 |g month:08 |g pages:bvab090 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jendso/bvab090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2021 |e 8 |b 01 |c 08 |h bvab090 | ||